You are here

ENTR-701

Vertex pays Entrada $224M for preclinical rare disease drug, opening new front in assault on dystrophy

Fierce Biotech

Thu, 12/8/22 - 10:35 am

Vertex Pharmaceuticals

Entrada Therapeutics

myotonic muscular dystrophy